The Zambia Medicines Regulatory Authority (ZAMRA), says it has intensified surveillance activities across the country, to ensure compliance with the recent medicine recall directive and prevent circulation of the affected medicines.

ZAMRA Public Relations Officer, Ludovic Mwape, notes that it will be conducting follow-up engagements with the suppliers of Deltaprim tablets and Cromohist eye drops, in order to fully establish its pathways and withdraw affected batches from the market.

He disclosed that inspections and monitoring of pharmaceutical outlets are ongoing to verify if distributors, wholesalers and retailers have withdrawn the affected batches from the market.

Mr Mwape stated that the defects identified are largely linked to manufacturing challenges or other factors such as storage and handling conditions that may also contribute to product quality deterioration.

The Authority also cautioned consumers to carefully check batch numbers and use alternative batches, different brands, or other treatment options as recommended by qualified health practitioners, while the recall process is ongoing.